Zhejiang Wolwo Bio-Pharmaceutical Co Ltd historical data
| Date | Open | High | Low | Close | Adj. close | Volume |
|---|---|---|---|---|---|---|
| 2021-11-09 | 51.790 | 55.210 | 51.780 | 54.950 | 52.766 | 3,231,076 |
| 2021-11-08 | 53.570 | 53.570 | 51.570 | 51.790 | 49.731 | 2,543,874 |
| 2021-11-05 | 53.090 | 54.180 | 52.880 | 53.100 | 50.989 | 1,389,047 |
| 2021-11-04 | 53.290 | 53.640 | 52.920 | 53.360 | 51.239 | 1,667,629 |
| 2021-11-03 | 51.930 | 53.470 | 51.800 | 53.040 | 50.932 | 2,126,703 |
| 2021-11-02 | 52.310 | 52.890 | 51.800 | 51.930 | 49.866 | 2,295,739 |
| 2021-11-01 | 53.900 | 54.360 | 52.200 | 52.500 | 50.413 | 2,425,510 |
| 2021-10-29 | 53.110 | 54.390 | 52.680 | 53.650 | 51.517 | 2,284,798 |
| 2021-10-28 | 52.690 | 53.890 | 52.100 | 53.020 | 50.912 | 2,273,792 |
| 2021-10-27 | 53.570 | 54.900 | 52.830 | 52.940 | 50.836 | 4,891,054 |
| 2021-10-26 | 56.230 | 56.600 | 55.430 | 55.750 | 53.534 | 2,527,577 |
| 2021-10-25 | 55.300 | 55.890 | 54.370 | 55.200 | 53.006 | 1,988,578 |
| 2021-10-22 | 55.150 | 55.670 | 54.610 | 55.260 | 53.063 | 1,523,524 |
| 2021-10-21 | 54.580 | 55.500 | 54.010 | 55.000 | 52.814 | 1,858,610 |
| 2021-10-20 | 55.000 | 55.630 | 53.250 | 54.170 | 52.017 | 2,267,759 |
| 2021-10-19 | 54.300 | 55.790 | 54.300 | 55.140 | 52.948 | 1,631,600 |
| 2021-10-18 | 56.990 | 57.300 | 54.040 | 54.300 | 52.142 | 2,904,218 |
| 2021-10-15 | 56.500 | 58.200 | 56.000 | 56.480 | 54.235 | 3,392,045 |
| 2021-10-14 | 59.710 | 60.500 | 55.920 | 56.100 | 53.870 | 5,022,535 |
← NewerPage 21 of 21 · 1,219 trading days
Stock splits
No stock splits on record.
Dividends
| Ex-date | Amount |
|---|---|
| 2026-07-09 | 0.1500 CNY |
| 2026-01-20 | 0.1000 CNY |
| 2025-07-08 | 0.1200 CNY |
| 2025-01-10 | 0.1000 CNY |
| 2024-07-04 | 0.1850 CNY |
| 2023-07-06 | 0.2000 CNY |
| 2022-06-16 | 0.2010 CNY |
| 2021-06-01 | 0.1600 CNY |
| 2020-05-21 | 0.1800 CNY |
| 2019-05-08 | 0.4500 CNY |
Open, high, low and close are as traded (CNY). Adjusted close accounts for splits and dividends. Educational only, not financial advice.